X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12088) 12088
Publication (1202) 1202
Book Review (183) 183
Book Chapter (95) 95
Dissertation (40) 40
Conference Proceeding (32) 32
Magazine Article (18) 18
Book / eBook (14) 14
Web Resource (10) 10
Government Document (7) 7
Data Set (4) 4
Reference (3) 3
Paper (1) 1
Presentation (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7494) 7494
female (7241) 7241
aromatase inhibitors (4901) 4901
index medicus (4776) 4776
breast cancer (3672) 3672
breast neoplasms - drug therapy (3534) 3534
oncology (3433) 3433
animals (2869) 2869
postmenopausal women (2610) 2610
aromatase (2450) 2450
tamoxifen (2392) 2392
aromatase inhibitors - therapeutic use (2223) 2223
male (1978) 1978
estrogen (1952) 1952
middle aged (1952) 1952
aromatase inhibitor (1936) 1936
endocrinology & metabolism (1804) 1804
aged (1585) 1585
cancer (1583) 1583
letrozole (1554) 1554
aromatase - metabolism (1455) 1455
adult (1432) 1432
antineoplastic agents, hormonal - therapeutic use (1393) 1393
breast neoplasms - pathology (1372) 1372
anastrozole (1266) 1266
tamoxifen - therapeutic use (1176) 1176
endocrine therapy (1136) 1136
postmenopause (1104) 1104
triazoles - therapeutic use (1079) 1079
nitriles - therapeutic use (1077) 1077
care and treatment (1068) 1068
women (1032) 1032
aromatase inhibitors - pharmacology (1029) 1029
obstetrics & gynecology (1019) 1019
biochemistry & molecular biology (1016) 1016
randomized-trial (978) 978
treatment outcome (946) 946
rats (928) 928
expression (921) 921
estradiol (919) 919
aromatase inhibitors - adverse effects (897) 897
breast neoplasms - metabolism (881) 881
analysis (838) 838
research (833) 833
chemotherapy, adjuvant (830) 830
pharmacology & pharmacy (830) 830
breast-cancer (790) 790
aromatase - genetics (779) 779
therapy (772) 772
medicine & public health (761) 761
health aspects (752) 752
antineoplastic agents - therapeutic use (747) 747
testosterone (726) 726
pregnancy (703) 703
article (690) 690
chemotherapy (653) 653
aged, 80 and over (642) 642
receptors, estrogen - metabolism (629) 629
enzyme inhibitors - pharmacology (627) 627
aromatase inhibitors - administration & dosage (623) 623
triazoles - pharmacology (619) 619
exemestane (613) 613
mice (605) 605
nitriles - pharmacology (572) 572
reproductive biology (569) 569
risk factors (566) 566
estrogens (540) 540
drug therapy (529) 529
estradiol - blood (526) 526
triazoles - administration & dosage (518) 518
nitriles - administration & dosage (508) 508
dose-response relationship, drug (507) 507
cell line, tumor (487) 487
double-blind (483) 483
chemistry, medicinal (481) 481
gene-expression (481) 481
breast neoplasms - genetics (479) 479
gene expression (467) 467
menopause (459) 459
clinical trials as topic (454) 454
enzyme inhibitors - therapeutic use (454) 454
estrogen-receptor (453) 453
adjuvant treatment (449) 449
breast neoplasms - enzymology (445) 445
antineoplastic agents, hormonal - adverse effects (444) 444
inhibitors (444) 444
estradiol - pharmacology (439) 439
hormones (430) 430
androstenedione - analogs & derivatives (425) 425
antineoplastic combined chemotherapy protocols - therapeutic use (425) 425
neoplasms, hormone-dependent - drug therapy (425) 425
trial (417) 417
disease-free survival (415) 415
enzymes (407) 407
cells (404) 404
prognosis (403) 403
estrogens - metabolism (402) 402
time factors (402) 402
prevention (401) 401
androgens (399) 399
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11677) 11677
French (161) 161
Japanese (123) 123
German (85) 85
Chinese (37) 37
Russian (33) 33
Spanish (21) 21
Hungarian (16) 16
Italian (15) 15
Polish (14) 14
Korean (13) 13
Czech (12) 12
Portuguese (11) 11
Danish (9) 9
Dutch (6) 6
Slovak (4) 4
Bulgarian (3) 3
Finnish (3) 3
Norwegian (3) 3
Swedish (3) 3
Croatian (2) 2
Hebrew (2) 2
Persian (2) 2
Romanian (2) 2
Turkish (2) 2
Ukrainian (2) 2
Bosnian (1) 1
Lithuanian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2008, 2nd rev. ed., Milestones in drug therapy, ISBN 3764386924, x, 189
Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the... 
Aromatase Inhibitors | drug therapy | Breast Neoplasms | therapeutic use | Clinical & internal medicine | Breast | Chemotherapy | Inhibitors | Aromatase | Therapeutic use | Cancer | Cancer Research | Oncology | Internal Medicine | Biomedicine | Pharmacology/Toxicology | Cell Biology
Book
2006, 1. Aufl., Milestones in drug therapy, ISBN 9783764374181, ix, 182
Book
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 01/2017, Volume 23, Issue 1, pp. 26 - 34
Purpose: Alpelisib, a selective oral inhibitor of the class I PI3K catalytic subunit p110 alpha, has shown synergistic antitumor activity with endocrine... 
ACTIVATION | NVP-BYL719 | PIK3CA MUTATIONS | PI3K | ONCOLOGY | PHOSPHATIDYLINOSITOL 3-KINASE | GROWTH | ESTROGEN DEPRIVATION | RESISTANCE | ALPHA | TUMORS | Triazoles - administration & dosage | Receptors, Estrogen - metabolism | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Thiazoles - administration & dosage | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Biomarkers, Tumor | Breast Neoplasms - metabolism | Nitriles - administration & dosage | Neoplasm Metastasis | DNA Mutational Analysis | Adult | Female | Aromatase Inhibitors - administration & dosage | Receptors, Estrogen - genetics | In Situ Hybridization, Fluorescence | Treatment Outcome | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Maximum Tolerated Dose | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Cell Line, Tumor | Aged | Mutation | Neoplasm Staging | Letrozole | Therapy | Toxicity | p53 Protein | Exanthema | Clinical trials | Metastasis | K-Ras protein | Metastases | Gene sequencing | Anticancer properties | Hyperglycemia | Safety engineering | Catalysis | Fibroblast growth factor receptor 1 | Deoxyribonucleic acid--DNA | Diarrhea | Endocrine therapy | Fatigue | Nausea | Breast cancer | Patients | ErbB-2 protein | 1-Phosphatidylinositol 3-kinase | Inhibitors | Experimental design | Breast | Antitumor activity | Tumors | DNA sequencing | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2016, Volume 375, Issue 3, pp. 209 - 219
Journal Article
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, pp. 4055 - 4065
Purpose: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor-positive (ER+) breast cancer. This single-arm phase II neoadjuvant... 
TRIAL | AROMATASE INHIBITOR | 1ST-LINE TREATMENT | RETINOBLASTOMA PROTEIN | ONCOLOGY | INTRINSIC SUBTYPE | IN-VIVO | DOUBLE-BLIND | LETROZOLE | CELL-PROLIFERATION | POSTMENOPAUSAL WOMEN | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Breast Neoplasms - surgery | Triazoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Class I Phosphatidylinositol 3-Kinases - genetics | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Nitriles - administration & dosage | Pyridines - adverse effects | Adult | Female | Neoadjuvant Therapy | Gene Expression Regulation, Neoplastic - drug effects | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Pyridines - administration & dosage | Breast Neoplasms - drug therapy | Piperazines - adverse effects | Disease-Free Survival | Breast Neoplasms - genetics | Estrogen Receptor alpha - genetics | Breast Neoplasms - pathology | Aged | Cell Proliferation - drug effects | Mutation | Neoplasm Staging | Cell proliferation | Anastrozole | Estrogens | Cyclin-dependent kinases | Estrogen | Estrogen receptors | Breast cancer | Kinases | Gene expression | Patients | ErbB-2 protein | Cyclin-dependent kinase 4 | Cyclin-dependent kinase | E2F protein | Inhibitors | Experimental design | Surgery | Cell cycle | Breast | Cancer | breast cancer | neoadjuvant | anastrozole | CDK4 | palbociclib
Journal Article
2008, 2nd rev. ed., Milestones in drug therapy, ISBN 3764386932
Web Resource